Details
Stereochemistry | ACHIRAL |
Molecular Formula | C21H20O6 |
Molecular Weight | 368.3799 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC=C(C=C1)C2=C(O)C(=O)C3=C(O)C=C(O)C(CC=C(C)C)=C3O2
InChI
InChIKey=TUUXBSASAQJECY-UHFFFAOYSA-N
InChI=1S/C21H20O6/c1-11(2)4-9-14-15(22)10-16(23)17-18(24)19(25)20(27-21(14)17)12-5-7-13(26-3)8-6-12/h4-8,10,22-23,25H,9H2,1-3H3
Molecular Formula | C21H20O6 |
Molecular Weight | 368.3799 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Icaritin is a monoprenylated favonol with 4′-methoxyl from Epimedium Genus. It has been documented to have osteoblastic and neuroprotective activities. It can reduce the incidence of steroid-associated oesteonecrosis in rabbit with inhibition of both intravascular thrombosis and extravascular lipid deposition for maintaining the integrity of intraosseous vasculature. Icaritin shows anti-infammatory activity and inhibitory activities against cancer cells. The phase III clinical trial is planned for the treatment of Hepatocellular carcinoma.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1075125 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24791596 |
|||
Target ID: CHEMBL3397 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24791596 |
|||
Target ID: IL-6/JAK2/STAT3 signaling Sources: https://www.ncbi.nlm.nih.gov/pubmed/25865044 |
|||
Target ID: CHEMBL4394 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28206952 |
|||
Target ID: CHEMBL242 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
7.89 ng/mL |
80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered: |
ICARIIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
10.08 ng/mL |
80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered: |
ICARISIDE II plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
279 ng × h/mL |
80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered: |
ICARIIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
255 mg × h/mL |
80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered: |
ICARISIDE II plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3.16 h |
80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered: |
ICARIIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
2.21 h |
80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered: |
ICARISIDE II plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT03236649
600 mg/time, 2 times/day
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21376032
Icaritin strongly inhibited the growth of breast cancer MDA-MB-453 and MCF7 cells. At concentrations of 2-3 uM, icaritin induced cell cycle arrest at the G(2)/M phase accompanied by a down-regulation of the expression levels of the G(2)/M regulatory proteins such as cyclinB, cdc2 and cdc25C. Icaritin at concentrations of 4-5 uM, however, induced apoptotic cell death characterized by the accumulation of the annexin V- and propidium iodide-positive cells, cleavage of poly ADP-ribose polymerase (PARP) and down-regulation of the Bcl-2 expression.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 08:13:46 GMT 2023
by
admin
on
Sat Dec 16 08:13:46 GMT 2023
|
Record UNII |
UFE666UELY
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DB12672
Created by
admin on Sat Dec 16 08:13:46 GMT 2023 , Edited by admin on Sat Dec 16 08:13:46 GMT 2023
|
PRIMARY | |||
|
118525-40-9
Created by
admin on Sat Dec 16 08:13:46 GMT 2023 , Edited by admin on Sat Dec 16 08:13:46 GMT 2023
|
PRIMARY | |||
|
DTXSID00152154
Created by
admin on Sat Dec 16 08:13:46 GMT 2023 , Edited by admin on Sat Dec 16 08:13:46 GMT 2023
|
PRIMARY | |||
|
5318980
Created by
admin on Sat Dec 16 08:13:46 GMT 2023 , Edited by admin on Sat Dec 16 08:13:46 GMT 2023
|
PRIMARY | |||
|
UFE666UELY
Created by
admin on Sat Dec 16 08:13:46 GMT 2023 , Edited by admin on Sat Dec 16 08:13:46 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |